Myriad Genetics, Inc. (NASDAQ: MYGN) open the trading on Thursday, with a bit cautious approach as it glided -3.49% to $17.98, before settling in for the price of $18.63 at the close. Taking a more long-term approach, MYGN posted a 52-week range of $13.82-$24.21.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 4.63%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 109.26%. This publicly-traded company’s shares outstanding now amounts to $89.90 million, simultaneously with a float of $86.02 million. The organization now has a market capitalization sitting at $1.62 billion. At the time of writing, stock’s 50-day Moving Average stood at $21.23, while the 200-day Moving Average is $19.17.
Myriad Genetics, Inc. (MYGN) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Diagnostics & Research industry. Myriad Genetics, Inc.’s current insider ownership accounts for 4.29%, in contrast to 101.53% institutional ownership. According to the most recent insider trade that took place on Dec 01 ’23, this organization’s Chief Financial Officer sold 30,000 shares at the rate of 19.09, making the entire transaction reach 572,835 in total value, affecting insider ownership by 291,812. Preceding that transaction, on Nov 01 ’23, Company’s Chief Financial Officer sold 30,000 for 15.69, making the whole transaction’s value amount to 470,622. This particular insider is now the holder of 321,812 in total.
Myriad Genetics, Inc. (MYGN) Earnings and Revenue Records
Myriad Genetics, Inc.’s EPS increase for this current 12-month fiscal period is 109.26% and is forecasted to reach 0.25 in the upcoming year.
Myriad Genetics, Inc. (NASDAQ: MYGN) Trading Performance Indicators
Let’s observe the current performance indicators for Myriad Genetics, Inc. (MYGN). It’s Quick Ratio in the last reported quarter now stands at 1.87. The Stock has managed to achieve an average true range (ATR) of 0.74. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.15.
In the same vein, MYGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.20, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be 0.25 at the market close of one year from today.
Technical Analysis of Myriad Genetics, Inc. (MYGN)
[Myriad Genetics, Inc., MYGN] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 12.61% While, its Average True Range was 0.68.
Raw Stochastic average of Myriad Genetics, Inc. (MYGN) in the period of the previous 100 days is set at 12.18%, which indicates a major rise in contrast to 1.91% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 29.85% that was lower than 46.78% volatility it exhibited in the past 100-days period.
